No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.

• Dong-E-E-Jiao Co.,Ltd.
• Ajanta Pharma Limited
• Humanwell Healthcare (Group) Co.,Ltd.
• Changchun High-Tech Industries (Group) Inc.
• Ipca Laboratories Limited
• Indivior Pharmaceuticals Inc
• Betta Pharmaceuticals Co., Ltd.
• J. B. Chemicals & Pharmaceuticals Limited